Cyclacel Pharmaceuticals Inc CYCC:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:50 PM EST
5.80quote price arrow down-0.30 (-4.92%)
Volume
2,319
Close
6.10quote price arrow down-0.66 (-9.76%)
Volume
597,708
52 week range
3.12 - 19.25

...

Loading . . .

KEY STATS

  • Open6.75
  • Day High6.89
  • Day Low5.71
  • Prev Close6.76
  • 52 Week High19.25
  • 52 Week High Date04/20/20
  • 52 Week Low3.12
  • 52 Week Low Date10/28/20
  • Market Cap43.31M
  • Shares Out7.10M
  • 10 Day Average Volume0.51M
  • Dividend-
  • Dividend Yield-
  • Beta1.22
  • 1 Year % Change-45.54

RATIOS/PROFITABILITY

  • EPS (TTM)-3.42
  • P/E (TTM)-1.78
  • Fwd P/E (NTM)-2.80
  • EBITDA (MRQ)-10.241M
  • ROE (MRQ)-42.55%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-5,029.33%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/14/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Cyclacel Pharmaceuticals Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate...
David U'Prichard Ph.D.
Chairman
Christopher Henney Ph.D.
Vice Chairman
Spiro Rombotis
President
Paul McBarron
Chief Financial Officer
Judy Chiao M.D.
Vice President
Address
200 Connell Dr Ste 1500
Berkeley Heights, NJ
07922-2811
United States